TAMPA, Fla., June 24, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA), a company at the forefront of Phase 3 immune-oncology research, has announced the initiation of its Phase 3 accelerated approval trial for IFx-2.0. This trial, focusing on patients with advanced or metastatic Merkel cell carcinoma (MCC), marks a significant milestone in TuHURA's efforts to enhance cancer immunotherapy. The trial is being conducted under a Special Protocol Assessment $(SPA.UK)$ agreement with the U.S. Food and Drug Administration (FDA). The initiation of this trial triggers the release of the third tranche of funds from a $12.5 million private placement financing, securing an additional $2.23 million for TuHURA. The financing is solely obtained by TuHURA Biosciences. This development is seen as a pivotal step in potentially overcoming resistance to checkpoint inhibitors in cancer treatment.